Replies to post #2342 on BioCryst Pharmaceuticals,Inc. (BCRX)

[vieuxcarre]

Will re enter in the 4s. After raise is announced

[Deano361]

Merck is our friend here IMO. Potential buyout from them is the $20+ price IMO

Presently, Jon P. Stonehouse is President, Chief Executive Officer & Director at BioCryst Pharmaceuticals, Inc.

He is also on the board of Bellicum Pharmaceuticals, Inc. and The North Carolina Museum of Life & Science, Inc.

In the past he occupied the position of SVP-Corporate Development & VP-Global Licensing at Merck KGaA and Vice President-Licensing & Business Development at EMD Pharmaceuticals, Inc. (a subsidiary of Merck KGaA), Director-Sales & Marketing for AstraZeneca Plc and Director-Marketing & Sales at Astra Merck, Inc. (a subsidiary of AstraZeneca Plc) and Manager-District Sales at Merck & Co., Inc.